Development Option. If GCLC desires to pursue development of a Product in combination with an antigen-specific therapy that Artiva has determined not to pursue, the Parties shall discuss in good faith and agree on a co-development arrangement for such Product in combination with such antigen-specific therapy in mutually agreed Indications in the Territory, which shall not overlap with Indications for which Artiva is developing a Product.
Appears in 4 contracts
Samples: Selected Product License Agreement (Artiva Biotherapeutics, Inc.), Selected Product License Agreement (Artiva Biotherapeutics, Inc.), Selected Product License Agreement (Artiva Biotherapeutics, Inc.)
Development Option. If GCLC desires to pursue development of a Product in combination with an antigen-specific therapy that Artiva has determined not to pursue, the Parties shall discuss in good faith and agree on a co-development arrangement for such Product in combination with such antigen-specific therapy in mutually agreed Indications in the Territory, which shall not overlap with Indications for which Artiva is developing a Product.
Appears in 4 contracts
Samples: Selected Product License Agreement (Artiva Biotherapeutics, Inc.), Selected Product License Agreement (Artiva Biotherapeutics, Inc.), Selected Product License Agreement (Artiva Biotherapeutics, Inc.)
Development Option. If GCLC desires to pursue development of a Product in combination with an antigen-specific therapy that Artiva has determined not to pursue, the Parties shall discuss in good faith and agree on a co-development arrangement for such Product in combination with such an antigen-specific therapy in mutually agreed Indications in the Territory, which shall not overlap with Indications for which Artiva is developing a Product.
Appears in 1 contract
Samples: Selected Product License Agreement (Artiva Biotherapeutics, Inc.)
Development Option. If GCLC GCC desires to pursue development of a Product in combination with an antigen-specific therapy that Artiva has determined not to pursue, the Parties shall discuss in good faith and agree on a co-development arrangement for such Product in combination with such an antigen-specific therapy in mutually agreed Indications in the Territory, which shall not overlap with Indications for which Artiva is developing a Product.
Appears in 1 contract
Samples: Selected Product License Agreement (Artiva Biotherapeutics, Inc.)